Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenue $ 189
Cost of revenue 369
Gross profit (loss) (180)
Operating expenses:        
Sales and marketing 4,898 1,875 8,823 3,262
General and administrative 11,839 6,837 21,436 10,211
Research and development 6,740 4,258 12,671 7,573
Total operating expenses 23,477 12,970 42,930 21,046
Loss from operations (23,477) (12,970) (43,110) (21,046)
Other income (expense):        
Interest expense (523) (523)
Change in fair value - Senior Secured Convertible Note (2,000) (2,000) 1,682
Loss on issue and offering costs - Senior Secured Convertible Note (3,101) (3,101)
Debt extinguishments loss - Senior Secured Convertible Notes (3,715)
Debt forgiveness 300 300
Other income (expense), net (5,624) 300 (5,624) (1,733)
Loss before provision for income tax (29,101) (12,670) (48,734) (22,779)
Provision for income taxes
Net loss before noncontrolling interests (29,101) (12,670) (48,734) (22,779)
Net loss attributable to the noncontrolling interests 3,576 1,199 6,337 1,877
Net loss attributable to PAVmed Inc. (25,525) (11,471) (42,397) (20,902)
Less: Series B Convertible Preferred Stock dividends earned (70) (74) (138) (149)
Net loss attributable to PAVmed Inc. common stockholders $ (25,595) $ (11,545) $ (42,535) $ (21,051)
Per share information:        
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.29) $ (0.14) $ (0.49) $ (0.27)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted $ (0.29) $ (0.14) $ (0.49) $ (0.27)
Weighted average common shares outstanding, basic and diluted 86,957,352 82,235,397 86,689,857 78,117,637